Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

Last updated:
2026-08-08
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF CILOFEXOR IN NON-CIRRHOTIC SUBJECTS WITH PRIMARY SCLEROSING CHOLANGITIS

Intervention/treatment:
CILOFEXOR (GS-9674)
Medical condition:
PRIMARY SCLEROSING CHOLANGITIS
Protocol code:
GS-US-428-4194
Control number:
226501
Status:
Closed
Approved:
May 02, 2019
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03890120
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Gilead Clinical Study Information Center
Organization
Gilead Sciences
Phone:
1-833-445-3230 (GILEAD-0)
Sponsor
GILEAD SCIENCES CANADA INC

Locations

(G.I.R.I.) GI Research Institute
Vancouver, V6Z 2K5
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)
Montreal, H2X 3J4
Chronic Viral Illness Service/McGill University Health Centre (MUHC)
Montreal, H4A 3J1
Gordon and Leslie Diamond Health Care Centre, Vancouver General Hospital, UBC Division of Gastroenterology
Vancouver, V5Z 1M9
McMaster University Medical Center
Hamilton, L8S 4L8
Queen Elizabeth II Health Sciences Centre, Nova Scotia Health Authority
Halifax, B3L 1E4
St. Joseph's Healthcare Hamilton
Hamilton, L8N 4A6
Toronto General Hospital - Toronto Centre for Liver Disease (TCLD)
Toronto, M5G 2C4
Toronto Liver Centre
Toronto, M6H 3M1
University of Alberta Hospital - Walter C. Mackenzie Health Sciences Centre (WMC)
Edmonton, T6G 2X8
University of Calgary Liver Unit - Heritage Medical Research Clinic (HMRC)
Calgary, T2N 4Z6
University of Manitoba/Health Sciences Centre
Winnipeg, R3E 3P4
William Osler Health System - Brampton Civic Hospital
Brampton, L6R 3J7

Results

See the results from the trial NCT03890120. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?